Amgen Inc. Other Revenue, Net (Deprecated 2018-01-31)
Amgen Inc. (AMGN) reported Other Revenue, Net (Deprecated 2018-01-31) of $211.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-25.
Discontinued › Income Statement › Other Income
us-gaap:OtherSalesRevenueNet · last filed 2018-04-25
- Amgen Inc. other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $211.00M, a 20.38% decline year-over-year.
- Amgen Inc. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $233.00M, a 22.85% decline year-over-year.
- Amgen Inc. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $320.00M, a 8.47% increase year-over-year.
- Amgen Inc. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $236.00M, a 10.28% increase year-over-year.
- Amgen Inc. other revenue, net (deprecated 2018-01-31) for fiscal 2017 was $1.05B, a 4.09% decline from fiscal 2016.
- Amgen Inc. other revenue, net (deprecated 2018-01-31) for fiscal 2016 was $1.10B, a 53.06% increase from fiscal 2015.
- Amgen Inc. other revenue, net (deprecated 2018-01-31) for fiscal 2015 was $718.00M, a 2.45% decline from fiscal 2014.
- Amgen Inc. other revenue, net (deprecated 2018-01-31) for fiscal 2014 was $736.00M.
| Period end | Other Revenue, Net (Deprecated 2018-01-31) 3 month | Other Revenue, Net (Deprecated 2018-01-31) 6 month | Other Revenue, Net (Deprecated 2018-01-31) 9 month | Other Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $211.00M 10-Q · filed 2018-04-25 | $444.00M derived: sum of 2 quarters · filed 2018-04-25 | $764.00M derived: sum of 3 quarters · filed 2018-04-25 | $1.00B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-12-31 | $233.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $553.00M derived: sum of 2 quarters · filed 2018-02-13 | $789.00M derived: sum of 3 quarters · filed 2018-02-13 | $1.05B 10-K · filed 2018-02-13 |
| 2017-09-30 | $320.00M 10-Q · filed 2017-10-26 | $556.00M derived: sum of 2 quarters · filed 2017-10-26 | $821.00M 10-Q · filed 2017-10-26 | $1.12B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-06-30 | $236.00M 10-Q · filed 2017-07-26 | $501.00M 10-Q · filed 2017-07-26 | $803.00M derived: sum of 3 quarters · filed 2018-04-25 | $1.10B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-03-31 | $265.00M 10-Q · filed 2018-04-25 | $567.00M derived: sum of 2 quarters · filed 2018-04-25 | $862.00M derived: sum of 3 quarters · filed 2018-04-25 | $1.08B derived: sum of 4 quarters · filed 2018-04-25 |
| 2016-12-31 | $302.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $597.00M derived: sum of 2 quarters · filed 2018-02-13 | $811.00M derived: sum of 3 quarters · filed 2018-02-13 | $1.10B 10-K · filed 2018-02-13 |
| 2016-09-30 | $295.00M 10-Q · filed 2017-10-26 | $509.00M derived: sum of 2 quarters · filed 2017-10-26 | $797.00M 10-Q · filed 2017-10-26 | $1.00B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $214.00M 10-Q · filed 2017-07-26 | $502.00M 10-Q · filed 2017-07-26 | $709.00M derived: sum of 3 quarters · filed 2018-02-13 | $916.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $288.00M 10-Q · filed 2017-04-27 | $495.00M derived: sum of 2 quarters · filed 2018-02-13 | $702.00M derived: sum of 3 quarters · filed 2018-02-13 | $847.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $207.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $414.00M derived: sum of 2 quarters · filed 2018-02-13 | $559.00M derived: sum of 3 quarters · filed 2018-02-13 | $718.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | $207.00M 10-Q · filed 2016-10-28 | $352.00M derived: sum of 2 quarters · filed 2016-10-28 | $511.00M 10-Q · filed 2016-10-28 | $668.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $145.00M 10-Q · filed 2016-07-29 | $304.00M 10-Q · filed 2016-07-29 | $461.00M derived: sum of 3 quarters · filed 2017-02-14 | $644.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $159.00M 10-Q · filed 2016-05-02 | $316.00M derived: sum of 2 quarters · filed 2017-02-14 | $499.00M derived: sum of 3 quarters · filed 2017-02-14 | $730.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $157.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $340.00M derived: sum of 2 quarters · filed 2017-02-14 | $571.00M derived: sum of 3 quarters · filed 2017-02-14 | $736.00M 10-K · filed 2017-02-14 |
| 2014-09-30 | $183.00M 10-Q · filed 2015-11-02 | $414.00M derived: sum of 2 quarters · filed 2015-11-02 | $579.00M 10-Q · filed 2015-11-02 | $791.00M derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-06-30 | $231.00M 10-Q · filed 2015-08-05 | $396.00M 10-Q · filed 2015-08-05 | $608.00M derived: sum of 3 quarters · filed 2016-10-31 | $709.00M derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-03-31 | $165.00M 10-Q · filed 2015-04-27 | $377.00M derived: sum of 2 quarters · filed 2016-10-31 | $478.00M derived: sum of 3 quarters · filed 2016-10-31 | $562.00M derived: sum of 4 quarters · filed 2016-10-31 |
| 2013-12-31 | $212.00M derived: 8-K 12 month − 10-Q 9 month · filed 2016-10-31 | $313.00M derived: sum of 2 quarters · filed 2016-10-31 | $397.00M derived: sum of 3 quarters · filed 2016-10-31 | $484.00M 8-K · filed 2016-10-31 |
| 2013-09-30 | $101.00M 10-Q · filed 2014-10-29 | $185.00M derived: sum of 2 quarters · filed 2014-10-29 | $272.00M 10-Q · filed 2014-10-29 | $356.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $84.00M 10-Q · filed 2014-08-05 | $171.00M 10-Q · filed 2014-08-05 | $255.00M derived: sum of 3 quarters · filed 2015-02-19 | $373.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $87.00M 10-Q · filed 2014-04-30 | $171.00M derived: sum of 2 quarters · filed 2015-02-19 | $289.00M derived: sum of 3 quarters · filed 2015-02-19 | $566.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $84.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $202.00M derived: sum of 2 quarters · filed 2015-02-19 | $479.00M derived: sum of 3 quarters · filed 2015-02-19 | $626.00M 10-K · filed 2015-02-19 |
| 2012-09-30 | $118.00M 10-Q · filed 2013-10-29 | $395.00M derived: sum of 2 quarters · filed 2013-10-29 | $542.00M 10-Q · filed 2013-10-29 | $608.00M derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-06-30 | $277.00M 10-Q · filed 2013-08-06 | $424.00M 10-Q · filed 2013-08-06 | $490.00M derived: sum of 3 quarters · filed 2014-02-24 | $557.00M derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-03-31 | $147.00M 10-Q · filed 2013-05-03 | $213.00M derived: sum of 2 quarters · filed 2014-02-24 | $280.00M derived: sum of 3 quarters · filed 2014-02-24 | $346.00M derived: sum of 4 quarters · filed 2014-02-24 |
| 2011-12-31 | $66.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $133.00M derived: sum of 2 quarters · filed 2014-02-24 | $199.00M derived: sum of 3 quarters · filed 2014-02-24 | $287.00M 10-K · filed 2014-02-24 |
| 2011-09-30 | $67.00M 10-Q · filed 2012-11-06 | $133.00M derived: sum of 2 quarters · filed 2012-11-06 | $221.00M 10-Q · filed 2012-11-06 | $302.00M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $66.00M 10-Q · filed 2012-08-08 | $154.00M 10-Q · filed 2012-08-08 | $235.00M derived: sum of 3 quarters · filed 2013-02-27 | $292.00M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | $88.00M 10-Q · filed 2012-05-08 | $169.00M derived: sum of 2 quarters · filed 2013-02-27 | $226.00M derived: sum of 3 quarters · filed 2013-02-27 | $417.00M derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $81.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $138.00M derived: sum of 2 quarters · filed 2013-02-27 | $329.00M derived: sum of 3 quarters · filed 2013-02-27 | $393.00M 10-K · filed 2013-02-27 |
| 2010-09-30 | $57.00M 10-Q · filed 2011-11-04 | $248.00M derived: sum of 2 quarters · filed 2011-11-04 | $312.00M 10-Q · filed 2011-11-04 | $378.00M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $191.00M 10-Q · filed 2011-08-08 | $255.00M 10-Q · filed 2011-08-08 | $321.00M derived: sum of 3 quarters · filed 2012-02-29 | $397.00M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | $64.00M 10-Q · filed 2011-05-10 | $130.00M derived: sum of 2 quarters · filed 2012-02-29 | $206.00M derived: sum of 3 quarters · filed 2012-02-29 | $285.00M derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $66.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $142.00M derived: sum of 2 quarters · filed 2012-02-29 | $221.00M derived: sum of 3 quarters · filed 2012-02-29 | $291.00M 10-K · filed 2012-02-29 |
| 2009-09-30 | $76.00M 10-Q · filed 2010-11-08 | $155.00M derived: sum of 2 quarters · filed 2010-11-08 | $225.00M 10-Q · filed 2010-11-08 | $302.00M derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-06-30 | $79.00M 10-Q · filed 2010-08-09 | $149.00M 10-Q · filed 2010-08-09 | $226.00M derived: sum of 3 quarters · filed 2011-02-25 | $317.00M derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-03-31 | $70.00M 10-Q · filed 2010-05-07 | $147.00M derived: sum of 2 quarters · filed 2011-02-25 | $238.00M derived: sum of 3 quarters · filed 2011-02-25 | $310.00M derived: sum of 4 quarters · filed 2011-02-25 |
| 2008-12-31 | $77.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $168.00M derived: sum of 2 quarters · filed 2011-02-25 | $240.00M derived: sum of 3 quarters · filed 2011-02-25 | $316.00M 10-K · filed 2011-02-25 |
| 2008-09-30 | $91.00M 10-Q · filed 2009-11-06 | $163.00M derived: sum of 2 quarters · filed 2009-11-06 | $239.00M 10-Q · filed 2009-11-06 | |
| 2008-06-30 | $72.00M 10-Q · filed 2009-08-10 | $148.00M 10-Q · filed 2009-08-10 | ||
| 2007-12-31 | $460.00M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |